Therapeutic peptides for diabetes and obesity — including insulin, GLP-1 agonists, and amylin analogs — can aggregate into amyloid-like clumps that reduce effectiveness and trigger immune reactions if not properly formulated and stored.
A century of peptide stability challengesFrom the first impure animal insulin preparations to today's recombinant semaglutide, peptide aggregation into amyloid-like structures remains a persistent challenge that can reduce drug activity and trigger immune responses.
What the researchers found
The review covers aggregation behavior across the major therapeutic peptide families used in metabolic disease:
- Insulin and insulin analogs — the original and most-studied therapeutic peptide, prone to amyloid fibril formation
- Amylin analogs (pramlintide, davalintide, cagrilintide) — based on a peptide that naturally forms amyloid in the pancreas
- GLP-1 receptor agonists (liraglutide, exenatide, semaglutide) — newer drugs with their own aggregation profiles
- Glucagon and related peptides
Improper formulation, storage, manipulation, and usage can lead to high molecular weight products (HMWP) that are either amorphous or amyloid in nature. These aggregates can cause loss of biological activity, short-term immune reactions, and long-term silent inactivation of the drug.
Why it matters
With hundreds of millions of people now using peptide drugs for diabetes and obesity, ensuring these medications remain stable and effective is a massive quality challenge. A single vial of insulin that has aggregated may look unchanged but deliver reduced or unpredictable dosing. Understanding why peptide drugs clump — and how to prevent it — is essential for patient safety, drug manufacturing, and the development of next-generation peptide therapeutics with improved stability profiles.
How the study worked
This is a narrative review synthesizing published research on the aggregation behavior of therapeutic polypeptides used in diabetes and metabolic diseases. The review covers aggregation mechanisms, analytical detection techniques, physical and chemical stability factors, and strategies for preventing high molecular weight product formation.
What this study cannot tell us
As a narrative review, the paper provides qualitative synthesis without meta-analysis or quantitative data from specific stability studies. The aggregation behavior of newer peptide drugs (like oral semaglutide and tirzepatide) may not be fully covered. Clinical evidence for immune reactions from aggregated peptide drugs in humans is limited and largely inferred from preclinical and in vitro studies. The review focuses primarily on physicochemical aspects rather than clinical outcomes.
How to read the evidence
This is a narrative review published in a biophysics/colloid science journal, providing expert perspective on peptide aggregation mechanisms. It synthesizes fundamental science and pharmaceutical research rather than clinical outcome data.
When this study was published
Published in 2022, this review is about 4 years old. The peptide drug landscape has evolved significantly since then with the explosion of GLP-1 agonist use for obesity, but the fundamental aggregation science remains relevant.
The bigger picture
Peptide aggregation is not just a manufacturing problem — it's a fundamental biophysics challenge that spans from Alzheimer's disease (amyloid-β) to diabetes (amylin/IAPP deposits in the pancreas) to drug stability. The same molecular forces that cause disease-associated protein misfolding also affect therapeutic peptides in a syringe or vial. As the peptide drug market expands dramatically — driven by GLP-1 drugs for obesity — solving aggregation problems becomes commercially and clinically more important than ever.
Questions still open
- Do patients using GLP-1 drugs experience clinically meaningful loss of efficacy from peptide aggregation under real-world storage conditions?
- How do newer dual and triple peptide agonists (tirzepatide, retatrutide) compare in aggregation propensity to single-target GLP-1 drugs?
- Could aggregation-resistant peptide designs improve the shelf life and real-world effectiveness of diabetes medications?
Common questions
Can my insulin or GLP-1 medication go bad from improper storage?
What happens if peptide medications aggregate?
Read the original research
Amyloidogenicity of peptides targeting diabetes and obesity.
Colloids and surfaces. B, Biointerfaces, 209(Pt 1), 112157
Citation
Lima, Luís Maurício T R; Icart, Luis Peña. (2022). Amyloidogenicity of peptides targeting diabetes and obesity.. Colloids and surfaces. B, Biointerfaces, 209(Pt 1), 112157. https://doi.org/10.1016/j.colsurfb.2021.112157